10-Q: NewAmsterdam Pharma Reports Q2 2026 Results, Faces Revenue Drop

NewAmsterdam Pharma Company N.V. reported its second-quarter 2026 financial results, showing a significant decrease in revenue and an increase in net loss, while advancing its obicetrapib development programs.

Summary

• NewAmsterdam Pharma Company N.V. reported a net loss of $64.1 million for the three months ended June 30, 2026, compared to a loss of $17.4 million in the same period of 2025.
• Revenue for the second quarter of 2026 was $3.7 million, a substantial decrease from $19.1 million in the second quarter of 2025, primarily due to the absence of a prior-year development cost contribution from Menarini.
• Research and development expenses increased by 52% to $41.7 million for the quarter, driven by clinical trial initiation and progression.
• Selling, general, and administrative expenses remained relatively stable at $26.9 million.
• As of June 30, 2026, the company held $678.3 million in cash, cash equivalents, and marketable securities.
• The company announced positive opinions from the EMA's CHMP for obicetrapib monotherapy and fixed-dose combination, with decisions expected later in 2026.
• An interim analysis of the PREVAIL cardiovascular outcomes trial is planned for Q4 2026, with results expected in Q1 2027.
• The company is exploring obicetrapib for Alzheimer's disease and has initiated a new clinical trial in this area.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant revenue decline, increased operating losses, and ongoing substantial cash burn, despite positive clinical trial developments.

Positives

• Positive opinion from the EMA's CHMP recommending marketing authorization for obicetrapib monotherapy and fixed-dose combination.
• Successful completion of enrollment in the REMBRANDT Phase 3 trial.
• Initiation of a new clinical trial for obicetrapib in patients with early Alzheimer's disease.
• Continued progress in the RUBENS Phase 3 trial with topline data expected by year-end 2026.
• Significant cash, cash equivalents, and marketable securities balance of $678.3 million as of June 30, 2026, providing substantial runway.
• Obicetrapib has demonstrated statistically significant LDL-C lowering in multiple Phase 3 trials.
• Obicetrapib has shown to be well-tolerated in over 3,500 patients across clinical trials.

Negatives

• Net loss for the three months ended June 30, 2026, increased to $64.1 million from $17.4 million in the prior year period.
• Revenue for the three months ended June 30, 2026, decreased by 81% to $3.7 million from $19.1 million in the prior year period.
• Research and development expenses increased by 52% to $41.7 million for the quarter.
• The fair value change in warrants resulted in a loss of $4.6 million for the quarter, compared to a gain of $2.6 million in the prior year period.
• Net foreign exchange losses of $0.5 million for the quarter, compared to a gain of $8.6 million in the prior year period.
• The company has an accumulated loss of $875.0 million as of June 30, 2026.
• The fair value of derivative warrant liabilities was $54.5 million as of June 30, 2026.

Risks

• Topline and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification procedures.
• The PREVAIL CVOT interim analysis may not detect a statistically significant treatment benefit, or the trial could be stopped for futility.
• Current and future legislation and executive actions affecting the healthcare industry, including drug pricing reforms (e.g., IRA), may impact the ability to sell products profitably.
• Marketing and reimbursement regulations in foreign jurisdictions, particularly in the EU, may materially affect the ability to market and receive coverage for products.
• Changes in U.S. government policies, including increased tariffs, could adversely affect business operations and increase production costs.
• The company's future success is highly dependent on the successful development, regulatory approval, and commercialization of obicetrapib.
• The company has a history of losses and expects to continue incurring significant losses for the foreseeable future.
• The company's ability to raise additional capital in sufficient amounts or on terms acceptable to it is a significant risk.

Future Outlook

The company expects to continue incurring significant losses for the foreseeable future. Future revenue generation is dependent on the successful development, regulatory approval, and commercialization of obicetrapib. The company plans to submit NDAs in the U.S. for obicetrapib monotherapy and the FDC shortly after each other. Menarini anticipates potential product launches in Germany and the UK in Q4 2026 if MAAs are approved. The PREVAIL CVOT is expected to be completed by the end of 2027, with an interim analysis in Q4 2026 and DSMB recommendation in Q1 2027. Topline data from the RUBENS trial is expected by year-end 2026. A new clinical trial for obicetrapib in early Alzheimer's disease is expected to be initiated in 2026.

Management Comments

• The Company is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated.
• We believe that obicetrapib has the potential to be a once-daily oral CETP inhibitor for lowering LDL-C, if approved.
• We plan to announce additional clinical data from the BROADWAY, TANDEM, and BROOKLYN trials during 2026.
• Our goal is to develop and commercialize an LDL-C lowering monotherapy and an FDC therapy, which offers the advantage of a single, low dose, once-daily oral pill, and fulfills the significant unmet need for an effective and convenient LDL-C lowering therapy.
• We expect to continue to incur significant losses for the foreseeable future.

Industry Context

StockSavvy.ai notes that NewAmsterdam Pharma operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on cardiometabolic diseases. The company's reliance on obicetrapib, a CETP inhibitor, places it in a niche with potential but also significant development and regulatory hurdles, as seen with previous CETP inhibitors. The increasing focus on drug pricing and reimbursement by governments globally, as highlighted by the IRA in the US and evolving regulations in the EU, presents a significant challenge for future commercialization and profitability.

Comparison to Industry Standards

• The company's R&D expenses as a percentage of revenue are extremely high, typical for early-stage biopharmaceutical companies heavily invested in clinical trials, but unsustainable long-term without significant revenue or financing.
• The net loss per share of $(0.52) for Q2 2026 is substantial, reflecting the high cost of drug development, a common characteristic in the industry.
• The company's cash burn rate, while significant, is supported by a substantial cash reserve, which is a critical factor for survival in the biopharma industry where drug development timelines are long and success is not guaranteed.
• The positive CHMP opinion for obicetrapib aligns with industry trends where novel mechanisms of action for LDL-C reduction are sought, but regulatory approval is a critical gating item.
• The company's strategy to pursue both monotherapy and fixed-dose combination products is a common approach in the pharmaceutical industry to broaden market appeal and therapeutic options.

Legal Proceedings

• The company is not party to any material pending legal proceedings.

Related Party Transactions

• In the ordinary course of business, the Company may enter into transactions with entities that are associated with a party that meets the criteria of a related party of the Company. These transactions are reviewed quarterly and to date have not been material to the Company's consolidated financial statements.

Stakeholder Impact

• Shareholders: Increased net loss and significant R&D expenses may impact share price, while positive clinical trial news and potential regulatory approvals offer upside potential. The company's substantial cash reserves provide a buffer.
• Creditors: The company's strong cash position and lack of significant debt suggest low immediate risk to creditors.
• Employees: Continued investment in R&D and commercial preparedness may lead to job growth, but ongoing losses and the need for future capital raises could create uncertainty.
• Customers (potential): If approved, obicetrapib aims to address unmet needs in LDL-C lowering, potentially benefiting patients with cardiovascular disease.
• Suppliers: The company has commitments for R&D and manufacturing services estimated at a maximum of $62.0 million, indicating ongoing business for suppliers.

Next Steps

• Announce additional clinical data from BROADWAY, TANDEM, and BROOKLYN trials during 2026.
• Menarini to receive decisions on MAAs from European regulators later in 2026.
• Potential launch of obicetrapib in Germany and the UK in Q4 2026 by Menarini, if MAAs are approved.
• Conduct an interim analysis of the PREVAIL CVOT in Q4 2026.
• Receive DSMB recommendation from the PREVAIL interim analysis in Q1 2027.
• Complete the PREVAIL trial by the end of 2027 if not stopped early.
• Initiate a new clinical trial evaluating obicetrapib in patients with early Alzheimer's disease in 2026.
• Expect topline data from the RUBENS Phase 3 trial by year-end 2026.

Key Dates

Recommendation

The company shows promising clinical development for obicetrapib with positive regulatory feedback in Europe, suggesting potential future revenue. However, the significant increase in net loss, substantial revenue decline, and ongoing high R&D expenses, coupled with the inherent risks of drug development and regulatory approval, warrant a cautious approach. The substantial cash balance provides a runway, but the path to profitability remains long and uncertain. Therefore, a 'hold' recommendation is appropriate, pending further clinical data, regulatory decisions, and a clearer path to commercialization and profitability.

Keywords

NewAmsterdam Pharma, obicetrapib, cholesteryl ester transfer protein inhibitor, LDL-C lowering, cardiovascular disease, biopharmaceutical, clinical trials, Alzheimer's disease